At Concert Pharmaceuticals, we are pioneering the use of deuterium chemistry to discover and develop innovative new medicines that positively impact patient care and address important medical needs.
Our innovative approach has already resulted in multiple drug candidates that are progressing in clinical development. Each of these novel candidates is a result of improving a drug using our deuterium chemistry, expanding the potential of an approved drug.
Our robust pipeline of new medicines is rapidly advancing to offer innovative ways to treat a broad range of disease areas, targeting pulmonary diseases, including cystic fibrosis, central nervous system (CNS) disorders, as well as autoimmune and inflammatory diseases.
Our DCE Platform drives product innovation, enabling us to design drug candidates to create differentiated properties and address patient needs. Leveraging our team’s deep experience in drug development, we identify opportunities where deuterium chemistry can create drug candidates that address needs in important disease areas.